Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of August 13, 2025 • 12:00 AM ET

Date/Time Source News Release
08/07/2025 04:30 PM EDT Business Wire Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
07/31/2025 08:30 AM EDT Business Wire Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
07/24/2025 08:30 AM EDT Business Wire Vistagen to Present at the BTIG Virtual Biotechnology Conference
07/15/2025 08:30 AM EDT Business Wire Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
06/25/2025 08:30 AM EDT Business Wire Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
06/17/2025 04:30 PM EDT Business Wire Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
06/12/2025 08:30 AM EDT Business Wire Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
06/02/2025 08:30 AM EDT Business Wire Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
05/28/2025 08:30 AM EDT Business Wire Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
05/23/2025 08:30 AM EDT Business Wire Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
Page

Additional News

As of August 13, 2025 • 12:00 AM ET

Date/Time Source News Release
08/08/2025 02:14 PM EDT SeekingAlpha Vistagen signals Q4 2025 Phase III data readout for fasedienol as pipeline advances
08/08/2025 02:13 PM EDT SeekingAlpha Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript
08/07/2025 07:20 PM EDT Zacks VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
08/07/2025 04:38 PM EDT SeekingAlpha VistaGen Therapeutics GAAP EPS of -$0.47 in-line
08/07/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, August 7th, 2025
08/07/2025 05:31 AM EDT US Earnings Reports Expected earnings - Vistagen Therapeutics Inc.
08/06/2025 06:15 PM EDT Zacks Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates
08/05/2025 10:00 AM EDT Zacks Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
06/17/2025 06:50 PM EDT SeekingAlpha Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline
06/17/2025 06:49 PM EDT SeekingAlpha Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.